Postgrad Med J 83:409-413 doi:10.1136/pgmj.2006.055905
  • Review

Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential

  1. Iain S Whitaker1,
  2. Christopher Twine2,
  3. Michael J Whitaker3,
  4. Mathew Welck4,
  5. Charles S Brown5,
  6. Ahmed Shandall6
  1. 1Department of Burns and Plastic Surgery, Morriston Hospital, Swansea, UK
  2. 2Department of General and Vascular Surgery, Royal Gwent Hospital, Newport, UK
  3. 3University of Cambridge clinical school, Cambridge, UK
  4. 4Department of Anatomy, Guy’s and St. Thomas’ Hospital, London, UK
  5. 5University of Louisville, Louisville, Kentucky, USA
  6. 6Department of General and Vascular Surgery, Royal Gwent Hospital, Newport, UK
  1. Correspondence to:
 Iain S Whitaker
 8 Avonlea Road, Sale M33 4HZ, UK; iainwhitaker{at}
  • Received 27 November 2006
  • Accepted 23 January 2007


When modern medicine fails, it is often useful to draw ideas from ancient treatments. The therapeutic use of fly larvae to debride necrotic tissue, also known as larval therapy, maggot debridement therapy or biosurgery, dates back to the beginnings of civilisation. Despite repeatedly falling out of favour largely because of patient intolerance to the treatment, the practice of larval therapy is increasing around the world because of its efficacy, safety and simplicity. Clinical indications for larval treatment are varied, but, in particular, are wounds infected with multidrug-resistant bacteria and the presence of significant co-morbidities precluding surgical intervention. The flies most often used in larval therapy are the facultative calliphorids, with the greenbottle blowfly (Lucilia sericata) being the most widely used species. This review summarises the fascinating and turbulent history of larval therapy from its origin to the present day, including mechanisms of action and evidence for its clinical applications. It also explores future research directions.


  • Funding: None

  • Competing interests: None